Psychedelic Integration

Psychedelic Integration

Also called: integration, integration therapy

Psychedelic integration is the work that follows a psychedelic session: making sense of what happened and turning it into concrete changes in behavior, relationships and routines. In clinical research it is the third phase, after preparation and the dosing session itself. It can be guided by a therapist or coach, shared in a group or done alone.

Where the term comes from

Psychedelic therapists have long stressed what happens after a session, but structured approaches are recent. A 2022 review of the concept found 24 distinct definitions and ten developed models of integration, all published since 2017. Its combined definition describes a process of revisiting and working through the experience so that its lessons are gradually brought into a person’s life.

What the research shows

Clinical trials include integration, but in very different amounts. In a Johns Hopkins trial of psilocybin for depression, participants had about eight hours of preparation and two to three hours of follow-up meetings in total. A trial at Imperial College London, comparing psilocybin with an antidepressant, gave about 20 hours of in-person support across screening, preparation, dosing and integration, plus up to six optional follow-up calls. A review of 11 psilocybin trials found the same three phases in each but different styles of therapy within them. No specific integration method has yet been tested well enough to be called evidence-based.

A lift in mood after a session is not the same thing as integration. A review of 48 studies with 1,774 participants found better mood and well-being between one day and one month after use, and noted that whether and how these effects turn into lasting benefit has yet to be shown.

How it differs from related ideas

Integration is more than retelling the experience. Integration therapists interviewed in one study described it as a bridge between the session and daily life that begins before the session itself. It overlaps with harm-reduction support, which is designed for people using psychedelics in any context, not only after supervised sessions. Our page on integration explains why we treat the months after a session as part of the work.

Related terms

Set and Setting: the mindset and environment of the session itself.

Psilocybin Contraindications: who should not take part in psilocybin sessions, and why.

Sources

Bathje, Majeski & Kudowor - Psychedelic integration: An analysis of the concept and its practice, Frontiers in Psychology, 2022 (24 definitions, ten models)

Davis et al. - Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial, JAMA Psychiatry, 2021 (Johns Hopkins trial)

Erritzoe et al. - Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression, Journal of Psychopharmacology, 2024 (support given in the Imperial trial)

Horton, Morrison & Schmidt - Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy, American Journal of Psychotherapy, 2021 (11 trials)

Greń et al. - Call for evidence-based psychedelic integration, Experimental and Clinical Psychopharmacology, 2024 (no model yet evidence-based)

Evens, Schmidt, Majić & Schmidt - The psychedelic afterglow phenomenon: A systematic review of subacute effects of classic serotonergic psychedelics, Therapeutic Advances in Psychopharmacology, 2023 (48 studies, 1,774 participants)

Earleywine, Low, Lau & De Leo - Integration in psychedelic-assisted treatments: Recurring themes in current providers’ definitions, challenges, and concerns, Journal of Humanistic Psychology, 2022 (interviews with integration therapists)

Gorman, Nielson, Molinar, Cassidy & Sabbagh - Psychedelic harm reduction and integration: A transtheoretical model for clinical practice, Frontiers in Psychology, 2021 (harm-reduction approach)